Mixed Autologous And Allogeneic Transplantation, A New Model To Establish Stable Mixed Cheimrsim  by Abedi, M. et al.
S284 Poster Session II338
ALLOGENEIC STEM CELL TRANSPLANTATION FOR T-CELL LYMPHOMA
Grosskreutz, C.L., Scigliano, E., Osman, K., Malone, A., Nieto, J.,
Isola, L.M. Mount Sinai Medical Center, New York, NY
Introduction: Results of conventional and even high-dose chemo-
therapy with ASCT for T-cell lymphomas are poor when compared
with their aggressive B-cell counterparts. We analyzed the results of
allogeneic stem cell transplantation in 23 patients with T-cell lym-
phoma at our Institution.
Patients andMethods:Gender: 15 males and 8 females with a me-
dian age of 43 years (19 to 65) underwent allogeneic HCT at
Mount Sinai Medical Center between 5/2000 and 8/2009. The
different histologic subtypes were: 8 PTCL, 6 hepatosplenic
T-cell lymphoma, 4 angioimmunoblastic T-cell lymphoma, 2
CTCL, 1 NK-T cell lymphoma, 1 ATLL, 1 anaplastic T-cell
lymphoma. Donor sources included 15 PBSC, 7 BM and 1 CB.
Donor types were: 13 related and 10 unrelated. Conditioning reg-
imens used were: NST (Flu/TBI200/ATG) 9 pts, RIC (Flu/Mel)
7pts, (Flu/Cy/Campath) 1 pt. and MA (TBI 1,200/Cy) in 6 pts.
Six patients had prior ASCT. The rest received allografting as
primary modality.
Results: Eight patients are alive in CR at a median of 637 days post-
transplant (149-1729). Four of the six patients who underwent prior
ASCT achieved CR after allogeneic HCT. Six patients died of pro-
gressive disease after allogeneic HCT.Nine patients died from com-
plications of GVHD and/or infection.
Conclusions: Allogeneic stem cell transplantation results in dis-
ease-free survival in a fraction of patients with T-cell lymphoma.
Some patients 4/6 achieved CR after allogeneic HCT even after
progression post ASCTx. This observation supports the existence
of clinically-relevant graft versus T-cell lymphoma allo-responses.
Whether this effect exists for all histologic sub-types of T-cell
lymphomas as well as the optimal timing and conditioning for
allografting for this disease are issues that deserve prospective
studies.339
REDUCED INTENSITY CONDITIONING (RIC) REGIMEN BASED ON FLU-
DARABINE (FLU) FOR PATIENTS TREATED WITH ALLO-SCT FOR SEVERE
APLASTIC ANEMIA (SAA)
Abello, V., Rosales, C., Pedraza, E., Linares, A., Esguerra,H., Rosales,M.,
Figueroa, J. Clınica de Marly, Bogota, Colombia
Allo-SCT is the treatment of choice for patients with SAA.
Reduced intensity Conditioning (RIC) has been used in the
past to ensure adequate engraftment and reduce mortality re-
lated to the procedure. Here we report a retrospective analysis
of our experience using a fludarabine based RIC in patients
with SAA.
Since 2006, 12 patients (1 Fanconi Anemia, 11 adquired SAA),
mean 38 years (13-60), 10 males, 2 females, have been treated
with HLA identical related RIC allo-SCT. Conditioning regimen
consisted of Flu (30 mg/m2/day  4 days), Cyclophosphamide
(Cy 10 mg/kg/day  4 days) and horse antithymocyte globuline
(ATG 2 mg/Kg/day  4 days). GVHD prophylaxis consisted in
Ciclosporine and metrotexate for 4 patients, cyclosporine and
MMF for 4 patients and cyclosporine alone in 4 patients. All
grafts were obtained from peripheral blood stem cells. All, but
1 patient, were considered high risk because of more than 20
transfusions before transplantation, co-morbidities (morbid obe-
sity, renal dysfunction, hepatic toxicity), age (3 patients were
over 50) or previous transplant (2 patients had previous second-
ary graft failure after conditioning containing Campath). Mean
time from diagnosis to transplantation was 21.1 months (4.1-
118.7).
One 13 year old patient, with history of multiple infections ex-
pired before stem cell infusion due to severe sepsis. 11 patients en-
grafted, average at 11 days (range 9-16) for neutrophils and 11 days
(range 8-14) for platelets. Transfusion and antibiotic support re-
quired was minimal. None of the patients developed mucositis, di-
arrhea or required parenteral nutrition. Acute GVHD was seen in 2
of evaluable patients; both of them grade IV gastrointestinal
disease, one required ATG treatment due to corticoid refractorydisease. Chronic GVDH was seen in 1 patient who developed
a nephrotic syndrome.
At a mean follow-up of 15 months (range 1-42), 11 patients are
alive and in remission of SAA.
This experience suggests that Flu based RIC protocol allows rapid
and sustained engraftment with minimal early toxicity even in high-
risk patients.
Multicenter prospective clinical trials with longer follow-up are
warranted to confirm our observation.340
REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION CAN ACHIEVE BOTH DISEASE CONTROL AND VERY GOOD
OUTCOMES IN ELDERLY (.60) PATIENTS WITH HEMATOLOGIC MALIG-
NANCIES
Meyers, G., Subbiah, N., Palmbach, G., Kovacsovics, T., Abar, F., Hayes-
Lattin, B., Gajewski, J., Dunn, A., Jacoby, C., Slater, S., Allen, B.,
Maziarz, R. Oregon Health and Science University, Portland, OR
With the rapidly escalating numbers of healthy, elderly patients
with hematologic malignancies, defining optimal therapy for this
patient group is necessary to improve control of the underlying dis-
ease without excess morbidity. The graft vs. malignancy effects as-
sociated with allogeneic hematopoietic stem cell transplantation
(HSCT) may offer disease control with acceptable toxicity. A stan-
dard approach to healthy, elderly patients with high-risk hemato-
logic malignancies involves reduced intensity conditioning
followed by allogeneic HSCT. We report the outcomes of 75 pa-
tients, age 60 to 74, treated with this approach from 2001 through
May 2009.
Conditioning regimens included Fludarabine/TBI (15); TBI
alone (3); Fludarabine/Melphalan (10); and Busulfan/Fludarabine/
TBI (47). Most patients had AML/MDS (53), with the rest compris-
ing NHL (10), CLL (6), CML (3), ALL (2), and plasma cell disorder
(1). Disease control was achieved prior to transplant in a majority of
patients (50 patients in CR, 25 not in CR or untreated). Donors in-
cluded matched unrelated (41) matched related (26), and mis-
matched unrelated (8).
Currently, the outcomes in this high-risk cohort include 47% of
patients are alive. In analyzing cause of death, recurrence accounted
for 38% deaths, with additional deaths from infection (23%),
GVHD (21%), organ failure (15%) and graft failure (1 patient,
3%). Acute GVHD was seen in 64% of patients, with grade 3-4
present in 19% of patients. Of the 65 patients evaluable for chronic
GVHD, 85% had cGVHD, with the majority having extensive
cGVHD. Of particular note, in the 25 patients not in CR at the
time of transplant, 60% were in CR at the last disease status
evaluation.
Outcomes despite aggressive non-transplant treatments in older
patients with hematologic malignancies remain dismal. Two year
survival rates for AML are below 30% due to the high rate of disease
relapse and complications. Alternative treatment options are neces-
sary and increasingly, allogeneic HSCT appears favorable. In this
report, we show very good outcomes in this elderly, high-risk patient
population not dissimilar to younger patients undergoing reduced
intensity transplantation. While relapse remains a large cause of
death in our cohort, it is encouraging to see that 60% of patients
not in CR were able to achieve complete remission in the post-
transplant setting. The goal will be to continue to optimize this treat-
ment approach with improvements in supportive care and disease
control.341
MIXED AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION, A NEW
MODEL TO ESTABLISH STABLE MIXED CHEIMRSIM
Abedi, M.1, Greer, D.2, Hassani, M.1 1UC Davis Medical Center, Sacra-
mento, CA; 2Roger Williams Medical Center, Providence, RI
Graft versus tumor (GVT) effect after allogeneic bone marrow
transplantation (BMT) for hematological malignancies has a potent
Poster Session II S285anti-cancer effect. The outcome of allogeneic BMT however, has
been negatively impacted by the increased mortality and morbidity
due to transplant related toxicities including graft versus host
(GVHD) disease. There is an urgent need for a transplant regimen
that can combine the benefits of high dose chemotherapy (as used
in autologous BMT) with the ones of graft versus tumor (GVT)
effects while decreasing the transplant related mortality and mor-
bidity, specifically due to GVHD and related immunosuppressive
medications. Establishing a stable and reproducible mixed chime-
rism status in the host may be an answer to this problem. However
most of the current transplant protocols can only result in transient
mixed chimerism quickly changing to full donor chimerism or
graft rejection. To be able to take advantage of mixed chimerism
in a transplant setting, it is essential to have a reliable, and clini-
cally practical transplant regimen that consistently results in stable
and predictable mixed chimerism. To achieve this goal, we simul-
taneously co-transplanted different ratios of allogeneic and synge-
neic marrow cells from B6.SJL mice and B6D2F1 mice into
B6D2F1 recipients. With this protocol we were able to achieve
a stable mixed chimerism lasting more than 6 months. The level
of mixed chimerism was very similar to the ratio of the cells given
at the time of transplant. We did not observe any GVHD in this
animals. We next used the same model in a full mismatch
B6.SJL into Balb/c transplant model. No stable mixed chimersm
was observed. However, administration of intrperitoneal cyclo-
phosphamide (Cy) 1 day after transplant, resulted in stable mixed
chimersim in all the animals. We were able to convert these stable
mixed chimersim to either donor or recipient phenotype by admin-
istration of allogeneic or autologous spleen cells. Even after DLI,
no evidence of overt GVHD was seen. Changes in timing of Cy
from day +1 to day 3-4 did not change the outcome of mixed chi-
merism. Interestingly, we observed some GVT effects in the ani-
mals that had mixed chimerism. The simplicity of this transplant
model with no need for any in-vitro manipulation of cells and
no need for GVHD prophylaxis, plus the reproducibility of the
mixed chimerism status, makes this an interesting approach for
the treatment of both benign and malignant hematological condi-
tions.342
NONMYELOABLATIVE AND REDUCED INTENSITY CONDITIONING IN AL-
LOGENEIC STEM CELL TRANSPLANTATION FOR MYELOFIBROSIS
Malone, A.K., Scigliano, E., Grosskreutz, C., Osman, K., Isola, L. Mount
Sinai School of Medicine, New York, NY
Introduction: The only potentially curable therapy for myelofi-
brosis is allogeneic transplantation. Traditionally, myeloablative
conditioning regimens have been utilized but have been limited
by high regimen related mortality (RRM), poor 5 year overall
survival, advanced patient age and comorbidities. For these rea-
sons, NST and RIC have become an attractive transplant mo-
dality. We analyzed the results of 16 consecutive patients with
MF transplanted using NST and RIC conditioning regimens
at our institution.
Patients andMethods:Gender: 11 males and 5 females with a me-
dian age of 58.5 years (27-68) underwent allogeneic HCT at
Mount Sinai Medical Center between 2002 and 2009. The different
disease subtypes were: idiopathic MF (8), post-PV MF (1), post-ET
MF (1) and MF in transformation to AML (6). Donor sources in-
cluded bone marrow (6) and peripheral blood stem cells (10). Re-
lated donors were used in 6 transplants and unrelated donors in
10. Conditioning regimens used were: NST (6), RIC (9) and MA
(1). Patients received CSA/MMF (9) or FK/MTX (7) for immuno-
suppression.
Results:Eight patients are alive with amedian follow-up of 329 days
(12-1925). Eight patients are dead due to: GVHD (2), infection (5)
andMOF (1). Three patients (19%) died from regimen-related mor-
tality prior to day 100 post-transplant. Of these, 2 died from sepsis
and 1 from MOF. All 14 evaluable patients achieved 100% donor
chimerism. No patients had graft failure or received DLI. Grade
II-IV aGVHD developed in 7 patients and grade IV in 2. Limited
chronic GVHD developed in 1 patient and extensive in 3.Conclusions:Myeloablative conditioning, comorbid conditions and
age are limitations for allogeneic HCT inMF. Our unselected series
demonstrates that NST andRICHCTare feasible, increase the pool
of eligible patients, are able to achieve a good donor chimerism and
have an acceptable rate of RRM and GVHD.343
THE ASSOCIATION OF FLUDARABIN, ORAL BUSULFAN AND THYMOGLO-
BULIN PRIOR TO MATCHED RELATED ALLO-SCT ALLOWS FOR HIGH
LONG TERM OUTCOME FOR BOTH PATIENTS WITH MYELOID OR LYM-
PHOID MALIGNANCIES: LONG TERM ANALYSIS OF A HOMOGENOUS CO-
HORT OF 100 CONSECUTIVE PATIENTS
Farnault, L., Esterni, B., Faucher, C., Furst, S., El Cheikh, J.,
Ladaique, P., Vey, N., Bouabdallah, R., Stoppa, A.M., Lemarie, C.,
Calmels, B., Castagna, L., Mohty, M., Chabannon, C., Blaise, D. Institut
Paoli-Calmettes, Marseille, France
We analysed 100 consecutive pts treated in a single centre with
a minimal and median follow-up of respectively 28 and 56 mths.
Diagnoses: acute leukemia (AL) (39%), myeloid malignancies
(HMY) (16%) (AL +HMY5 55%) and lymphoid malignancies
(HLY) (45%); all pts were treated with PBSC allo-SCT from
a matched-related donor. RIC: oral bu (8 mg/m2), thymoglobu-
line (2.5 mg/kg) and fludara (150 mg/m2 over 5 days) and. Me-
dian age:50 (18-64). Respectively 53, 14 and 33 pts were in
CR, progression or stable disease (AL +HMY: 85%, 13%, 2%;
HLY: 13%, 16%, 71%, p\.0001). EBMT disease stage evalua-
tion was early (0-1), intermediate (2-3), and high stage (4-6)
for respectively 5, 52, 41 pts (AL +HMY: 7%, 73%, 20%;
HLY: 2%, 27%, 71%, p\.0001). HCT-CI was 0, 1-2 and .2
in 31, 39 and 23 of the 92 assessable pts (AL +HMY: 36%,
35%, 29%; HLY: 25%, 56%, 19%, p5NS). All but one en-
grafted. aGVHD and cGVHD CI were 43% (33-54) and 81%
(73-89) respectively. cGVHD was associated with low CD34
dose (.0001) and previous Grade$ 2 aGVHD (.036). DLI was
administered in 16 pts for mixed chimerism or disease progres-
sion in respectively 3 and 13 cases. TRM CI at 12 mths and 5
years were 15% (8-22) and 25% (16-34) respectively. TRM
was strongly associated with aGVHD (p5 .00004) but not with
EBMT score nor HCT-CI index. Overall, on the 56 assessable
pts, 36 (64%) achieved objective response (no difference between
2 groups). Relapse/progression occurred at a median of 11 mths
(1-52) in respectively 21 pts for a CI of 22.4% (11-33.7) and
22.5% (8.7-36.2) respectively in AL +HMY and HLY groups.
In a landmark analysis, disease progression was associated with
the absence of grade $2 aGVHD (p5 .0045) and the absence
of cGVHD (p5 .0035). 5 years OS and PFS probabilities were
63% (51-78) and 61% (49-75) for HMY + LA and 55%(42-72)
and 45%(31-64) for HLY. In multivariate analysis, improved
PFS was related to CR at transplantation (p5 .009) and low
CD34 dose (under median) (p5 .028). Results suggested a high
efficiency of a RIC combining Fludarabin and limited myeloabla-
tion (busulfan) and limited thymoglobuline dose in a wide popu-
lation in term of age, HSCT-CI, EBMT disease stage evaluation
for both lymphoid and not lymphoid malignancies. Lower stem
cell dose (but not other graft cells) was associated with more
cGVHD and improved PFS. This observation deserves further
investigation, notably inviting to revisit the impact of GCSF mo-
bilization in RIC context.344
A SINGLE CENTRE REVIEW INVESTIGATING WHETHER THE TRANSPORT
TIMES OF MUD STEM CELLS INFLUENCES ENGRAFTMENT TIMES POST
HSCT
Wood, C.1, D’Souza, A.1, Carter, J.M.1,2 1Wellington Hospital, Welling-
ton, New Zealand; 2University of Otago, Wellington, New Zealand
Aim:To analyse the impact that travel times and the wait time before
infusion has on neutrophil and platelet engraftment and overall mor-
tality in recipients of unrelated donor stem cells.
